NeuroBo Pharmaceuticals (NRBO) shares were up nearly 8% in recent trading Wednesday after the company reported its Q2 results.
The company reported Q2 net loss of $1.85 per diluted share, widening from a loss of $0.15 a year earlier.
Three analysts surveyed by Capital IQ expected a loss of $1.12
The company did not report revenue for the quarter ended June 30.
NeuroBo Pharmaceuticals said it had $27.9 million in cash as of June 30 and expects its cash position to fund the company's operations into Q2 2025.
Price: 4.01, Change: +0.29, Percent Change: +7.80
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。